BTG Pharmaceuticals
Thomas G. Kolaras has extensive work experience in the pharmaceutical industry, holding various senior leadership roles. Thomas G. is currently the Chief Commercial Officer (CCO) at BTG Specialty Pharmaceuticals since 2022. Prior to that, they worked at Endo Pharmaceuticals, where they held several positions, including Senior Vice President US Specialty Marketing, Vice President Marketing Specialty & Established Products, Vice President & General Manager Pain Business Unit, Vice-President Commercial Strategy & Patient Access, and Vice- President and General Manager, Urology Business Unit. In 2020, they joined Endo Pharmaceuticals again as the Senior Vice President, GM Medical Therapeutics. Additionally, they founded and served as the President of SteelCut Marketing from 2014 to 2015. Thomas G. also worked at Otsuka America Pharmaceutical, Inc. as the Vice-President, U.S. CNS Patient and Branding Strategy from 2011 to 2014. Prior to that, they had roles at Eisai Pharmaceuticals as Vice-President Primary Care & Specialty Marketing, Executive Director, Marketing, and Group Franchise Director. Thomas G. started their career at Novartis Consumer Health and Janssen Pharmaceutica, where they held various marketing, training, and sales roles.
Thomas G. Kolaras obtained a Bachelor of Science (BS) degree in Engineering from the University of Wisconsin-Madison, completing their education between the years 1983 and 1989.
This person is not in any offices
BTG Pharmaceuticals
1 followers
BTG is a dedicated ally to healthcare providers treating patients with critical conditions, focusing on emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain. Improving patients’ quality of life and offering hope is what motivates and inspires us. BTG was acquired by SERB Pharmaceuticals in 2020. SERB now operates in the US as BTG Pharmaceuticals.